1-(4-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidine, 95.0%, 5g

HEXETIDINE, 95%, 250mg

4-(4-Ethylphenyl)-4-oxobutyric acid, 95.0%, 25g

(3-Fluoro-5-methylpyridin-4-yl)boronic acid, 95.0%, 1g

SB 216763>98.0%(HPLC)10mg

(2-Methyl-5-(piperidin-1-ylsulfonyl)phenyl)boronic acid, 95.0%, 100mg

Ethyl 6-methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate, 96%, 250mg

(4-Fluorophenyl)(4-phenylpiperazin-1-yl)acetic acid, 250mg

4-Chlorocinnoline, 95.0%, 100mg

Abbe condenser 1.25 NA with opening for dark field and phase contrast slide. Without dark field slide and without phase contrast slides

z-d-phe-oh, 98.0%, 10g

1-((S)-4-fluoro-4-methyl-2-((S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)biphenyl-4-yl)ethylamino)pentanamido)cyclopropanecarboxamide, 98%, 25mg

Tert-butyl(5s)-5-amino-2-oxo-piperidine-1-carboxylate, 98%, 1g